About RayThera
RayThera is a Healthcare company based in San Diego (United States) founded in 2023 by Gene Hung and Qing Dong, and was acquired by Biogen in June 2026. Small molecule therapies for immunology unmet needs are developed. RayThera has raised $110 million across 1 funding round from investors including Biogen, Orbimed and Foresite Capital. Its chief executive, as recorded, is Qing Dong. RayThera offers products and services including Small Molecule Therapies and Innovative Drug Solutions. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its legal entity is RayThera, Inc.
Company details
RayThera was founded in 2023 and is based in San Diego, United States. Operations center on drug discovery in the immunology sector, where small molecule therapies are advanced to address unmet medical needs. Expertise is applied to accelerate development while standards are upheld. Transformative treatments are pursued to enhance patient outcomes in immunology.
- Headquarters San Diego, United States
- Founders Gene Hung, Qing Dong
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website raythera.com
- Acquired by Biogen (Jun 2026)
- Legal Name Raythera, Inc
Products & Services of RayThera
RayThera offers a comprehensive portfolio of products and services, including Small Molecule Therapies and Innovative Drug Solutions.
Small molecule therapies are developed for critical unmet needs in immunology, with an emphasis on accelerating the process while upholding rigorous standards.
Innovative drug solutions are provided that aim to transform patient care through adaptable approaches in drug discovery.
Funding Insights of RayThera
RayThera has successfully raised a total of $110M through 1 strategic funding round. The most recent funding activity was a Series A round of $110 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110M
- Total Rounds 1
- Last Round Series A — $110M
- First Round $110M
(Apr 2025)
- Investors Count 3
All 1 funding rounds of RayThera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $110M | Series A | – | Foresite Capital |
4 investors in total: 4 institutional.
Investors in RayThera
RayThera has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, Orbimed and Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
A leading Chinese venture capital firm in healthcare is operated. | ttmcapital.com | Shanghai, China | ||
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States |
Investor details for RayThera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RayThera
2 people are tracked at RayThera (2 in leadership).
| Name | Role | Group |
|---|---|---|
Gene Hung | Co-Founder & CSO | Leadership |
Qing Dong | Co-Founder & CEO | Leadership |
Complete people profiles for RayThera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of RayThera
3 dated milestones of RayThera across 3 years, from founding to its latest funding, stage changes and deals.
- Founded RayThera is founded.
- Funding First funding round of $110.0M.
- Exit Acquired by Biogen.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as RayThera (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about RayThera
RayThera was founded in 2023 and raised its 1st funding round 2 years after it was founded.
RayThera is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Qing Dong is the CEO of RayThera, as recorded in our data. They have also founded this company.
RayThera is a funded company, having raised a total of $110M across 1 funding round to date. The company's 1st funding round was a Series A of $110M, raised on Apr 2025.
RayThera was founded in 2023 and is based in San Diego, United States. Operations center on drug discovery in the immunology sector, where small molecule therapies are advanced to address unmet medical needs. Expertise is applied to accelerate development while standards are upheld. Transformative treatments are pursued to enhance patient outcomes in immunology.
RayThera offers Small Molecule Therapies and Innovative Drug Solutions.
RayThera has 4 investors. Key investors include Biogen, Orbimed, Foresite Capital, and TTM Capital.
RayThera operates through Raythera, Inc.
Yes. RayThera was acquired by Biogen in June 2026.